AXA S.A.
- SEC CIK
- 0000898427
- Latest filing
- Aug 14, 2026
LVTX holding history
LAVA Therapeutics NV in every 13F filed by AXA S.A., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
LVTX overviewAll 13F holders of LVTXFull Q2 2026 holdings
- Shares (Q2 2023)
- 0
- Sold out in Q2 2023
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 9
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2023 | 0 | $0 | 0.0% | −225,748−100.0% | Sold out | Holders |
| Q1 2023 | 225,748 | $374.7K | <0.1% | −1,733−0.8% | Reduced | Holders |
| Q4 2022 | 227,481 | $796.2K | <0.1% | −1,190−0.5% | Reduced | Holders |
| Q3 2022 | 228,671 | $1.05M | <0.1% | +1,198+0.5% | Added | Holders |
| Q2 2022 | 227,473 | $671.0K | <0.1% | −4,413−1.9% | Reduced | Holders |
| Q1 2022 | 231,886 | $1.02M | <0.1% | +20.0% | Added | Holders |
| Q4 2021 | 231,884 | $1.27M | <0.1% | +2,763+1.2% | Added | Holders |
| Q3 2021 | 229,121 | $1.36M | <0.1% | +8,458+3.8% | Added | Holders |
| Q2 2021 | 220,663 | $2.40M | <0.1% | +300+0.1% | Added | Holders |
| Q1 2021 | 220,363 | $3.35M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.